HAIXI PHARMA's above-limited price public offering in Hong Kong received 3,165.1 times subscription
I'm PortAI, I can summarize articles.
HAIXI PHARMA announced its global offering results, issuing 11.5 million H shares, with 10% allocated to the Hong Kong public offering and 90% to the international offering. The offer price per share is HKD 86.40, with a net fundraising of approximately HKD 940 million from the global offering. The subscription multiple for the Hong Kong public offering is 3165.1 times, while the international offering is 6.3 times. H shares are expected to begin trading on the Stock Exchange of Hong Kong on October 20, 2025
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments